Given the tremendous savings that generic drugs provide their patients, you would think doctors would know to turn to generics, but that is not always the case. To help educate them, some health care companies are turning to what is called counter detailing. Kathleen Jaeger, president and CEO of the Generic Pharmaceutical Association tells the Chicago Tribune's Bruce Japsen about counter detailing efforts by the generic drug industry, health plans and others as a way to spur more interest in cheaper medications.
Counter Detailing: Advancing the Generic Drug Movement

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Given the tremendous savings that generic drugs provide their patients, you would think doctors would know to turn to generics, but that is not always the case. To help educate them, some health care companies are turning to what is called counter detailing. Kathleen Jaeger, president and CEO of the Generic Pharmaceutical Association tells the Chicago Tribune's Bruce Japsen about counter detailing efforts by the generic drug industry, health plans and others as a way to spur more interest in cheaper medications.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
Partnering with Patients: Building Effective Communication and Support in HF Care
A Practical Guide to Prescribing in HF
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?